chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received COVID-19 vaccine today at 3pm. At 330pm patient requested to see a nurse. She stated the tip of her tongue felt numb. Had a similar reaction after her first vaccine, but more of the tongue was numb the first time. It went away after a day. She has not other numbness or deficits. She is requesting to have her vitals checked.
i got a covid 19 infection; i got a covid 19 infection; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51-year-old male patient received BNT162b2 (BNT162B2), on 15Apr2021 at 12:00 as dose 1, single (Lot number: ew0164), in left arm, on 06May2021 at 12:00 as dose 2, single (Lot number: ew0167), in left arm and on 11Nov2021 as dose 3 (booster), single (Lot number: paa173696) at the age of 51 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LOSARTAN; ATORVASTATIN; SERTRALINE.  The following information was reported: VACCINATION FAILURE (medically significant) with onset 20May2022 at 12:00, outcome "unknown", COVID-19 (medically significant) with onset 20May2022 at 12:00, outcome "recovered" and all described as "i got a covid 19 infection". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (20May2022) Positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of vaccination failure, covid-19.  Clinical course: The COVID-19 vaccine was administered at Doctor's office/urgent care. the patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. The AE did not result in emergency room or physician office visit.  No follow-up attempts are possible. No further information is expected.
Symptom: Armpit pain  Time course: constant   May be related to swollen lymph nodes in the armpit.
Muscle ache, fatigue, drowsiness, brief confusion, bilateral headache, onset 11 AM,  duration 2-3 hours
I was recently diagnosed with a suspected case of sudden onset pericarditis.  I was diagnosed by ER physicians  at the Hospital, and held overnight for additional tests and observation.  The condition resolved within hours after being treated with intravenous anti-inflammatory medication (Toridol) and oral inflammatory medication (Colchicine).
Patient reports pain in deltoid muscle of both arms.  Cannot tolerate pressure over muscle without pain.  Symptoms resolved on or about 11/15/2005.  Information received received May 2, 2006. The year of 2003 is the only information regarding the AE onset date/time that we have. 07/09/03 is the date of the vaccination (time is unknown).
Red rash in crotch area and underneath the armpit, near the rear. Itches and red rash has spread further. Outside of that, no adverse impact thus far. NOTE: I've never had an adverse reaction from a flu shot before. Right now, I'm guessing that the rash will eventually fade.
Client felt lightheaded and stated " I am going to pass out"  She was positioned on the floor.  Client was given cool compress, she declined water/juice and snack.   symptoms resolved within 10 mins, client was advised to continue to push fluids through out the day and report any additional symptoms to the school nurse on duty.
pt recvd vax 13MAR93 & w/in 2 hrs of vax exp pain @ inject site; also had trouble sleeping & exp pain in arm;
Progressive exanthem (10 out of 10 in intensity) started at thighs and then spread to rest of body from head to toe. Other symptoms included fever, diarrhea, irritability, decreased appetite, legs and scrotal edema. This started 9 days post vax. Discharge dx: gastroenteritis, allergic exanthem - both resolved on discharge.
This spontaneous report was received from a pharmacist refers to a 63 year old female patient with. The patient was allergic to latex, crab meat and sactive. No pertinent medical history were reported. On 06-JAN-2014, the patient was vaccinated with ZOSTAVAX lot # J007858, 0.65 ml, subcutaneous in the left arm. Concomitant medication included FLUZONE. On an unknown date in January 2014, after receiving ZOSTAVAX, the patient experienced pain in her left arm at the injection site and decreased range of motion of her left arm. The patient sought medical attention and called the pharmacy. The outcome of the events pain in her left arm at the injection site and decreased range of motion of her left arm was reported as not recovered. The reported did not provided the causality between the event and the suspect drug. Additional information has been requested.
Information has been received from a health professional concerning a male child who on 07/09/1999, at his 15-month checkup, was vaccinated with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation)(lot # 630623/0348J).  Concommitant vaccination on 07/09/1999 included diphtheria toxoid (+) pertussis vaccine (+) tetanus toxoid (manufacturer unknown).  The child's mother reported that on 07/13/1999 the child developed a swollen thigh from which he subsequently recovered.  In follow-up it was reported that the child did not received the second dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation) vaccination at his 4-year old checkup.  The child was given poliovirus vaccine inactivated and diphtheria toxoid (+) pertussis vaccine (+) tetanus toxoid and subsequently developed swelling with the diphtheria toxoid (+) pertussis vaccine (+) tetanus toxoid.  The reporter no longer felt that the swelling was related to the measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation).  It was unknown if the patient had received medical attention for his experience.  No further information is expected.
diarrhea; little warning on when it is going to occur; diarrhea for over 72 hours; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea), FEELING ABNORMAL (little warning on when it is going to occur) and DIARRHOEA (diarrhea for over 72 hours) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (diarrhea), FEELING ABNORMAL (little warning on when it is going to occur) and DIARRHOEA (diarrhea for over 72 hours). At the time of the report, DIARRHOEA (diarrhea), FEELING ABNORMAL (little warning on when it is going to occur) and DIARRHOEA (diarrhea for over 72 hours) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Fever...102...started approximately 10 hours after 2nd vaccine...took Tylenol every 6 hours the following day.  Fever was reduced but it wasn?t until the next day that it totally left.  Diarrhea, nauseated, weak, slept a lot.  Am feeling better today ( Sunday) but still a little weak.  I had no problems at all with the first Moderna vaccine.   No treatment.  Symptoms resolved over time.
pt returned later in day 18NOV93 w/persistent crying, t102.6 R & difficult to arouse from sleep; tx w/APAP 19NOV93 triage call t103 F tx w/APAP & sponge bath; 20NOV93 extended hrs acute care call t103 F; diarrhea, vomiting;
This case was reported by a pharmacist via call center representative and described the occurrence of erythematous rash n a 61-year-old female patient who received SHINGRIX (batch number 7FY22, expiry date 25th April 2020). On 26th May 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On 29th May 2018, 3 days after receiving SHINGRIX, the patient experienced erythematous rash. On an unknown date, the outcome of the erythematous rash was not recovered/not resolved. It was unknown if the reporter considered the erythematous rash to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on left deltoid at 10:15 hours. The patient experienced a red rash on the lower back a few days after receiving the SHINGRIX vaccine. It was reported that, the rash seemed to get worse after the patient exercised.
pain in rib cage; Uncomfortable; something burning; Hard to breath; Inflammation; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Uncomfortable), BURNING SENSATION (something burning), DYSPNOEA (Hard to breath), INFLAMMATION (Inflammation) and MUSCULOSKELETAL CHEST PAIN (pain in rib cage) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040A21A) for COVID-19 vaccination.     The patient's past medical history included Hepatitis C. Concurrent medical conditions included Psoriasis (psoriasis stage 4), Thyroid disorder and Hypertension.    On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (Uncomfortable), BURNING SENSATION (something burning), DYSPNOEA (Hard to breath), INFLAMMATION (Inflammation) and MUSCULOSKELETAL CHEST PAIN (pain in rib cage). At the time of the report, FEELING ABNORMAL (Uncomfortable), BURNING SENSATION (something burning), DYSPNOEA (Hard to breath), INFLAMMATION (Inflammation) and MUSCULOSKELETAL CHEST PAIN (pain in rib cage) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter No treatment information was provided
This spontaneous report has been received from a medical assistance referring to a patient of unknown age and gender. Information regarding the patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications was not provided. On 14-MAR-2018, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated(VAQTA) lot # M036458 with expiration date of 02-MAR-2018, 0.5 ml by intramuscular route (strength and anatomical location were not provided) for prophylaxis. No adverse effects were reported.
The next morning the patient woke up with a large ball under her axillae (likely enlarged lymph node)  she states it was very large;  she states it lasted 10 days and was very painful
Patient recieved vaccine, reported on 11/7 area was red, warm and itchy. Area involved was elbow to injection site. Did not recieve medical attention at that time.  Called again 11/8/15 reported that it looked less red but was worried about cellulitis.  Patient was considering visiting urgent care.  Spoke with patient on 11/13/15, symptoms resolved without medical intervention.
Vaccine was administered to patient and a few moments later the patient stated she felt lightheaded. She then lost consciousness and began to make a snoring sound as if she had difficulty breathing/wasn't breathing well. I caught her in her chair and immediately told my technician to call EMS in case of anaphylaxis, and I grabbed an epi-pen. However, the patient then came back to consciousness and was breathing normally. She stated she felt lightheaded still but was getting better. She also stated she had no difficulty breathing and airway clear. She was monitored for 15-30 minutes nearby the pharmacy and paramedics showed up, but patient denied treatment. She told them what had happened and stated she was feeling better, but just wanted to sit for a bit. Patient contacted her husband to pick her up so she did not have to drive.
This case was received from a health care professional on 01 May 2009. It was reported as one of a cluster of three patients, the other two patients' event are captured in case numbers 2009-01931 and 2009-01932. A five-year-old female patient received the following vaccinations on 28 April 2008: a left arm fifth dose of DAPTACEL (lot number C3084AA), a left arm fourth dose of IPOL (lot number B0475-2), and a right arm second dose of MMRII ( Merck, lot not reported). On 30 April 2009, the patient's parent reported a red, swollen left arm. The area was treated with cool compresses. Outcome was not reported. Follow-up information was received from the health care professional on 22 May 2009. The patient recovered.
Morning following injection, MOP noticed redness, swelling, warm to touch, tenderness, lump at left thigh injection site. Symptoms lasted approximately 2 more days. Primary Care Provider saw patient 3 days following and noted much less symptoms at time of encounter. No treatments were done at that time.
PATIENT NOTED WITH LARGE REDDENED HARDENED SWELLING TO RIGHT DELTOID/BICEP AREA, WARM TO TOUCH, PAIN TO TOUCH (6/10).
Patient reports receiving the vaccine at a pharmacy other than mine. She states that night she had 2 asthma attacks and carried a low grade fever for 48 hours
DEVELPED A LOW GRADE FEVER AT SCHOOL AND WAS SENT HOME. 10/31/09 STARTED DEVELOPING A RASH ON ARMS LEGS BACK AND TORSO AREAS. PROBABLY ABOUT 20 SPOTS, GIVEN BENEDRYL TO STOP THE REACTION AND THE ITCHING.
MOTHER STATES SHE HAD A HARD REDDENED AREA ON HER RIGHT THIGH.  PT STOPPED BY AND AREA WAS MEASURED on 3/5/2012, 50X55mm dark reddened hard area and 80x80mm raised area.
pt recvd vax;3-4 days p/ dose 2, exp flu-like sxs, d, anorexia, yellow eyes & dark-colored urine;
I have had 5 vaccinations since 22Dec2020 and have just tested positive for COVID for the first time; I have had 5 vaccinations since 22Dec2020 and have just tested positive for COVID for the first time; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from medical information team and product quality group, Program ID: (Unknown). The reporter is the patient.  A female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 12Nov2022 as dose 5 (booster), single (Lot number: GJ6796) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 24Dec2022, outcome "unknown" and all described as "I have had 5 vaccinations since 22Dec2020 and have just tested positive for COVID for the first time". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (24Dec2022) positive; (26Dec2022) positive.  Clinical course: I am wondering if my last COVID vaccine was an older version. I was expecting one that it would provide protection against the most recent strains. I have had 5 vaccinations since 22Dec2020 and have just tested positive for COVID for the first time (24Dec2022 and still positive on 26Dec2022). This was very disappointing. My last vaccine was 12Nov2022 from #: GJ6796.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the available information in the case, an association between the reported events DRUG INEFFECTIVE  & COVID-19 and The suspected drug cannot be ruled out.,Linked Report(s) : US-PFIZER INC-2021010707 same reporter/patient, different dose/events;
ROTATEQ vaccine was administered at the age of 9 months 26 days. No reactions and no further treatment.
9/16 HIV blood test resulted as reactive on 9/16. Blood sent for further testing on 9/16. Results came back negative on 9/22
I started to feel bad kind of chills in the evening, headache, I went and tested myself it was negative. In the morning of the next day I was super tired, chills, overwhelming feeling of bad and a stomach on 29DEC2022 COVID-19 test, positive. I had difficulty breathing but I thought I would be fine but I kept getting worse and I lost my taste and smell with a pretty bad headache and stomach ache with massive diarrhea so I made a doctors appointment somewhere around seven days into my illness to late for PAXLOVID but I did get a nebulizer with an antibiotic shot. The rest was home remedies vapor rub and staying in bed. I was extremely tired and recovery was longer than expected.
Patient stated about a week after vaccination, developed a hard, itchy/painful rash on the arm (she called "COVID arm") along with flu-like symptoms which included fever and body aches. She said the flu-like symptoms lasted for a couple of days, but the rash lasted for about 2 weeks.
Pt recv vax & 1 1/2 hr later pt exp fatigue, vertigo, chills, nausea & fever; sx lasted approx 2 hr lab eval on19MAY94 revealed a pos titer; A MD recommended that pt not receive the 3rd dose; No further details were provided;
This case was reported by a consumer via call center representative and described the occurrence of fever in a 69-year-old female patient who received SHINGRIX for prophylaxis. On 7th November 2018, the patient received the 2nd dose of SHINGRIX (intramuscular). On 7th November 2018, less than a day after receiving SHINGRIX, the patient experienced pain in arm. On 8th November 2018, the patient experienced fever, tiredness and headache. On an unknown date, the outcome of the fever, tiredness, headache and pain in arm were not recovered/not resolved. It was unknown if the reporter considered the fever, tiredness, headache and pain in arm to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in left deltoid. The patient experienced arm pain. On the reporting day, 1 day after receiving SHINGRIX, the patient woke up with feeling feverish, tired and a headache.
Presented with cough/sob. Dx + Covid 4 days PTA; Found to have COVID-19 pneumonia and acute hypoxic respiratory failure.  Coid symptoms x10 days; CXR: multifocal PNA; His condition worsened and he was requiring high-flow nasal cannula.  Started on IV antibiotics, remdesivir (1/26), baricitinib(2/1) , anticoagulation, Vit C, Vit D3, Zinc.  He had atrial fibrillation-Started on full-dose anticoagulation.  His condition worsened, intubated (2/7) and transferred to medical ICU.  Patient and family was not interested in aggressive measures however they agreed for intubation for a brief period of time.  After intubation his condition continued to get worsen.  He had respiratory acidosis and worsening renal function. Creatinine worsened to 5.54 family refused dialysis. Family decided on  scomfort care measures; pt expired
First dose was given on 13-Aug-21 and second dose was given in Dec-2021; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was given on 13-Aug-21 and second dose was given in Dec-2021) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis.    No Medical History information was reported.   On 13-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In December 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Solution for injection in pre-filled pen. In December 2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was given on 13-Aug-21 and second dose was given in Dec-2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was given on 13-Aug-21 and second dose was given in Dec-2021) outcome was unknown.            No concomitant medication information provided. It was unknown if patient was enrolled in Covid-19 vaccine trial. No treatment information provided.   This case was linked to MOD-2022-601340 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 05-Jul-2022: Follow up contains no new information.
Per patient rigors, chills, and lips turned blue x 1hr.  Did not seek medical attention.
injection site warmth; injection site rash; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (injection site warmth) and VACCINATION SITE RASH (injection site rash) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (injection site warmth) and VACCINATION SITE RASH (injection site rash). At the time of the report, VACCINATION SITE WARMTH (injection site warmth) and VACCINATION SITE RASH (injection site rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided. No treatment information provided.
next day:  Severely painful eyes,   photosensitivity,   this continued and increased until I saw Dr. ( my eye doctor) at hospital in another area>   He then saw me, agreed it was in response to Covid vaccination, and reported to me that he would rather I have this than lying in ICU.  HE then ordered FML steroid eye drops ( on a taper dose) and increased my compound 1 % cyclosporine eye drops from 4 x / day to 6 x / day.  After 4 days of that, I finally started to feel less pain. ALSO  I had occasional weakness of anterior tibialis.   After vaccination ( days later, and continues to today)  I get weakness and inability to dorsiflex almost nightly.   (Autonomic nerve problem exacerbated)
Severe chest pain at heart. Was taken to ER and given Morphing for pain. Was diagnosed with Myocarditis.; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot number: EN6205), via an unspecified route of administration on 26Feb2021 at 07:00 am on the left arm as a single dose for COVID-19 immunisation. Patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Lot number: EN6201), via an unspecified route of administration on 05Feb2021 at 07:00 am on the left arm as a single dose for COVID-19 immunisation. The patient had no known allergy. The patient's medical history included IGA. The patient's concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient medications two weeks prior vaccination included Losartan, Atorvastatin, Atenolol. Prior to vaccination, patient was not diagnosed with COVID-19. COVID prior vaccination was none. Since the vaccination, patient had not been tested for COVID-19. COVID tested post vaccination was none. On 28Feb2021 at 06:00 pm, the patient experienced Severe chest pain in the heart. The patient was taken to ER was and given Morphine for pain. Patient was diagnosed with Myocarditis. The case was assessed as Serious (Myocarditis). The patient visited the emergency room for the events. The patient was treated with morphine and inflammation drugs for the events. The outcome of the events was resolved.